Scope
NICE CG178 combines early access to specialist assessment with antipsychotic treatment, psychological interventions and sustained physical-health care. It distinguishes an at-risk mental state from established first-episode psychosis, and requires treatment response, adverse effects and relapse risk to be reviewed with the person throughout recovery.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Distinguish increased risk from established psychosis
- Refer without delay when distress and declining social function coexist with attenuated or transient psychotic symptoms, other possible psychotic experiences or behaviour, or a first-degree relative with psychosis or schizophrenia. Assessment should be by a psychiatrist or specialist experienced in at-risk mental states. [1]
- For an increased-risk mental state, offer individual CBT with or without family intervention and treat accompanying anxiety, depression, emerging personality disorder or substance misuse. Do not use antipsychotics solely to reduce risk or prevent psychosis. [1]
- If symptoms, impairment or distress continue without a clear psychosis diagnosis after treatment, monitor with a structured validated tool for up to 3 years. Adjust frequency to symptoms, impairment, distress and family concern. [1]
- Provide prompt early-intervention assessment for first-episode psychosis regardless of age or untreated duration. Primary care should not start antipsychotics for a first sustained presentation without consultant-psychiatrist consultation; use crisis services if urgent needs exceed early-intervention capacity. [1]
- Undertake multidisciplinary assessment covering psychiatric symptoms, risk, alcohol and drug history, physical illness or medicines that may cause psychosis, physical wellbeing, trauma, development and social or occupational needs. Monitor coexisting depression, anxiety and substance misuse. [1]
Combine treatments and agree the initial plan
- For first-episode psychosis, offer oral antipsychotic medication together with family intervention and individual CBT. If psychological treatment alone remains the informed preference, offer it, monitor closely and agree a review within 1 month or less to reconsider medication. [1]
- Choose an antipsychotic jointly, including carers’ views if the person agrees. Discuss metabolic, movement-related, cardiovascular and prolactin effects as well as unpleasant subjective experiences and the expected benefits. [1]
- Before prescribing, record weight, waist circumference, pulse, blood pressure, fasting glucose or HbA1c, lipids, prolactin, movement abnormalities, nutritional status, diet and physical activity. Offer an ECG when required by the product information, cardiovascular risk or disease is present, or admission is planned. [1]
- Treat prescribing as an explicit individual trial: document target benefits and tolerable adverse effects, start at the lower licensed range and titrate slowly. Justify out-of-range dosing and allow 4–6 weeks at an optimum dose when evaluating response. [1]
Monitor clinical response and physical safety systematically
- Monitor symptoms, functioning, adverse effects, movement disorders and adherence, especially during titration. Distinguish akathisia from agitation or anxiety; record weight weekly for 6 weeks, then at 12 weeks, 1 year and annually. [1]
- Measure waist circumference annually. Check pulse, blood pressure, fasting glucose or HbA1c and lipids at 12 weeks, 1 year and annually. Secondary care retains physical-health and medication-effect monitoring for at least 12 months or until stable, whichever is longer, before shared-care transfer. [1]
- Review as-needed antipsychotic indication, use, benefit and adverse effects weekly or as appropriate, checking total dose limits. Do not rapidly escalate or repeatedly give high doses for acute psychosis; avoid regular antipsychotic combinations except brief periods such as switching drugs. [1]
- Offer combined healthy-eating and physical-activity support and help with smoking cessation. Reducing smoking can materially change drug metabolism, particularly clozapine and olanzapine; address weight gain, dyslipidaemia and abnormal glucose through the relevant medical pathways. [1]
Deliver adequate psychological treatment and a workable crisis plan
- Deliver individual CBT over at least 16 planned sessions using an evidence-based manual where possible. Family intervention should span 3 months to 1 year, include at least 10 planned sessions, and incorporate supportive or educational work with negotiated problem solving or crisis management. [1]
- Offer CBT and family intervention during acute illness or recovery, including inpatient care, and continue a course after discharge without unnecessary interruption. Consider arts therapy, particularly for negative symptoms, with an appropriately registered and experienced therapist. [1]
- Use crisis-resolution and home-treatment services when acute community needs or risk exceed existing teams’ capacity, considering this before admission where appropriate. For an immediate risk requiring rapid tranquillisation, follow the separate violence, aggression and self-harm pathways. [1]
Plan relapse prevention and assess treatment resistance carefully
- Explain the high relapse risk from stopping medication in the next 1–2 years after an acute episode. If withdrawing, reduce gradually and monitor regularly; continue relapse monitoring for at least 2 years after withdrawal. Review maintenance medication at least annually. [1]
- Consider a long-acting injectable when preferred after an acute episode or when avoiding covert non-adherence is a clinical priority. Do not routinely use intermittent maintenance; consider it only when continuous treatment is unacceptable or contraindicated, such as because of adverse-effect sensitivity. [1]
- Before declaring non-response, review diagnosis, adherence, dose and duration, access to psychological treatment, substance use, concurrent medicines and physical illness. Offer clozapine after inadequate response to adequate sequential trials of at least 2 antipsychotics, including at least 1 non-clozapine second-generation drug. [1]
- For inadequate response to optimized clozapine, review the same causes and therapeutic drug levels before adding another antipsychotic. Augmentation may need 8–10 weeks; choose a drug that does not compound common clozapine adverse effects. [1]
- ECT is an option for rapid short-term treatment of severe catatonia when other treatment fails or the condition is life-threatening. It is not recommended for general schizophrenia management. [1]
- Agree information-sharing with carers, offer early carer education and support, and support employment or alternative occupational activity. [1]
- Consider re-referral from primary care for poor response, non-adherence, intolerable adverse effects, substance misuse or risk. Suspected relapse should activate the crisis plan and consideration of contact with the named clinician or care coordinator. [1]
Limitations and use
- This is adult psychosis and schizophrenia guidance. Affective psychosis follows the linked bipolar or depression pathway. Drug-specific doses, clozapine prescribing and laboratory safety protocols, and rapid-tranquillisation regimens are not established by this summary; consult their dedicated prescribing guidance.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Psychosis and schizophrenia in adults: prevention and management
Selected recommendation material consulted
Publication details
- Issuing organisation
- NICE
- First published
- 12 February 2014
- Publisher’s latest update
- 4 September 2026
- Resource type
- Clinical guideline · House clinical summary
- Source setting
- United Kingdom
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.